SCHEMBL7250393

SCHEMBL7250393

O=[N+]([O-])c1cc(OCc2ccccc2)ccc1-c1ccc(OC(F)(F)F)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTGES O14684 4/20 0.57
GSTP1 P09211 2/20 0.48
MRGPRX4 Q96LA9 1/20 0.46
FFAR1 O14842 1/20 0.45
FFAR4 Q5NUL3 1/20 0.45
MEN1 O00255 2/20 0.45
KMT2A Q03164 2/20 0.45
NPC1 O15118 1/20 0.45
RAB9A P51151 1/20 0.45
ATM Q13315 1/20 0.45
LMNA P02545 1/20 0.44
MAPT P10636 1/20 0.44
XBP1 P17861 1/20 0.44
MAPK1 P28482 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
TDP1 Q9NUW8 1/20 0.44
EIF4E P06730 1/20 0.44
TOP1 P11387 1/20 0.43
CYP19A1 P11511 1/20 0.43
CYP11B1 P15538 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7251777 0.88 PTGES (0.60) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL7256025 0.85 PTGES (0.61) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL1181925 0.85 PTGES (0.58) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL7251545 0.84 PTGES (0.57) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL7250749 0.84 PTGES (0.57) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL4204697 0.84 PTGES (0.57) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL7250438 0.84 PTGES (0.57) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL7251977 0.84 PTGES (0.54) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL7257197 0.81 PTGES (0.54) PTGESGSTP1MEN1KMT2ANPC1
SCHEMBL1182264 0.81 PTGES (0.54) PTGESGSTP1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030040538-A1 Novel substituted tricyclic compounds ASAHI-KASEI KABUSHIKI KAISHA (JP) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040538-A1 Novel substituted tricyclic compounds CPT1A, CBR1, NR1H3 PTGES 2801/4885GSTP1 984/4885MRGPRX4 1305/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.